Authors:
Quraishi, MS
Bessell, EM
Clark, DM
Jones, NS
Bradley, PJ
Citation: Ms. Quraishi et al., Aggressive sino-nasal non-Hodgkin's lymphoma diagnosed in Nottinghamshire,UK, between 1987 and 1996, CL ONCOL-UK, 13(4), 2001, pp. 269-272
Authors:
Bessell, EM
Graus, F
Lopez-Guillermo, A
Villa, S
Verger, E
Petit, J
Holland, I
Byrne, P
Citation: Em. Bessell et al., CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma, INT J RAD O, 50(2), 2001, pp. 457-464
Authors:
Hancock, BW
Gregory, WM
Cullen, MH
Hudson, GV
Burton, A
Selby, P
Maclennan, KA
Jack, A
Bessell, EM
Smith, P
Linch, DC
Citation: Bw. Hancock et al., ChlVPP alternating with PABIOE is superior to PABIOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial, BR J CANC, 84(10), 2001, pp. 1293-1300
Authors:
Foran, JM
Rohatiner, AZS
Cunningham, D
Popescu, RA
Solal-Celigny, P
Ghielmini, M
Coiffier, B
Johnson, PWM
Gisselbrecht, C
Reyes, F
Radford, JA
Bessell, EM
Souleau, B
Benzohra, A
Lister, TA
Citation: Jm. Foran et al., European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma, J CL ONCOL, 18(2), 2000, pp. 317-324
Authors:
Cartmill, M
Allibone, R
Bessell, EM
Byrne, PO
Citation: M. Cartmill et al., Primary cerebral non-Hodgkin's lymphoma: problems with diagnosis and development of a protocol for management, BR J NEUROS, 14(4), 2000, pp. 313-315
Authors:
Byrne, JL
Stainer, C
Cull, G
Haynes, AP
Bessell, EM
Hale, G
Waldmann, H
Russell, NH
Citation: Jl. Byrne et al., The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia, BONE MAR TR, 25(4), 2000, pp. 411-417
Citation: Em. Bessell et al., Severe hypoglycaemia caused by raised insulin-like growth factor II in disseminated breast cancer, J CLIN PATH, 52(10), 1999, pp. 780-781
Authors:
Bessell, EM
Moloney, AJ
Ellis, IO
Fletcher, J
Dowling, F
Citation: Em. Bessell et al., Prognostic factors affecting disease-free survival in patients with Hodgkin's disease stages IA and IIA treated initially with radiotherapy alone in a single centre during 1973 to 1992, RADIOTH ONC, 49(1), 1998, pp. 15-19